About Contact Us Careers

Medication-assisted Treatment (MAT) Market Size and Forecast, by Treatment Type (Drug Type, Counseling & Therapies); End User (Hospitals, Home Care Setting, Rehabilitation Clinic) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 5814
  • Published Date: Nov 28, 2025
  • Report Format: PDF, PPT
Festive Special Offer
$4550 $2450

Medication-assisted Treatment (MAT) Market Outlook:

Medication-assisted Treatment (MAT) Market size was valued at USD 11.2 billion in 2025 and is set to exceed USD 26.03 billion by 2035, registering over 8.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of medication-assisted treatment is estimated at USD 12.09 billion.

Medication-assisted Treatment (MAT) Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

This can be attributed to the rising prevalence of substance use disorder among individuals. According to recent information, around 286 Million people aged 15-64 used drugs worldwide in 2020, a 26 percent increase over the past decade.

In addition, with the advancement in medications and therapies such as the availability of a variety of medications like methadone, naltrexone. There is a continuous improvement in behavioral therapies and pharmacological treatments which is enhancing the efficacy of medication-assisted treatment. Moreover, the development of long-acting formulations and innovative delivery methods is also driving the medication-assisted treatment market growth.

Key Medication-assisted Treatment (MAT) Market Insights Summary:

  • Regional Highlights:

    • By 2035, the North America region is projected to secure about 45% share in the medication-assisted Treatment Market, supported by intensified funding for MAT programs, expanded treatment capacity, and broader regulatory integration into mainstream healthcare owing to increased institutional backing.
    • The Europe region is anticipated to account for nearly 30% share by 2035, as its multidisciplinary healthcare framework strengthens MAT adoption through integrated psychosocial support and community-driven harm-reduction initiatives.

  • Segment Insights:

    • The drug type segment in the medication-assisted treatment market is forecast to capture roughly 56% share by 2035, reinforced by rising pharma innovation and growing acceptance of MAT solutions impelled by advancements supporting substance-use recovery.
    • The hospital segment is projected to command nearly 53% share by 2035, as hospitals’ specialized care capabilities and structured inpatient MAT programs enhance treatment effectiveness, stimulated by intensive medical supervision.

  • Key Growth Trends:

    • Increase in Substance Abuse Deaths
    • Rising Awareness of Medication assisted Treatment (MAT)

  • Major Challenges:

    • Regulatory Challenges across Regions

  • Key Players: Indivior PLC, Mallinckrodt Pharmaceuticals, Titan Pharmaceuticals Inc., Alkermes plc, Orexo AB, Mylan N.V., Teva Pharmaceutical Industries Ltd., Lupin Limited, Hikma Pharmaceuticals PLC, Novartis AG.

Global Medication-assisted Treatment (MAT) Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 11.2 billion
    • 2026 Market Size: USD 12.09 billion
    • Projected Market Size: USD 26.03 billion by 2035
    • Growth Forecasts: 8.8%

  • Key Regional Dynamics:

    • Largest Region: North America (45% Share by 2035)
    • Fastest Growing Region: Europe
    • Dominating Countries: United States, Canada, United Kingdom, Germany, France
    • Emerging Countries: India, China, Brazil, Mexico, Australia

    • Last updated on : 28 November, 2025

Growth Drivers

  • Increase in Substance Abuse Deaths- Drug overdose deaths have been increasing rapidly and are among one of the reasons for mortality across the globe. According to the World Health Organization, about 600000 deaths were attributed to drug use in the year 2019. In addition, the rise in substance abuse deaths catalyzes the recognizing the urgency of implementing evidence-based interventions like MAT, leading to increased acceptance, adoption, and growth in the medication-assisted treatment market.  Furthermore, substance abuse often coexists with mental health disorders, contributing to the complexity of treatment. MAT, by addressing both addiction and mental health aspects, becomes a comprehensive solution that stimulates the market.
  • Rising Awareness of Medication-assisted Treatment (MAT)- Health organizations and advocacy groups conduct public education campaigns to spread information about the effectiveness of MAT in treating substance use disorder. In addition, increased media coverage of substance abuse issues and the role of MAT in treatment amplifies awareness. News stories, documentaries, and interviews with experts influence public opinion and encourage individuals to seek medication-assisted treatment when facing addiction challenges which stimulates the market. Furthermore, positive testimonials and success stories from individuals who have benefited from MAT contribute to the growth of the medication-assisted treatment market.   
  • Emergence of Technological Innovation- The integration of digital health tools, such as mobile applications and web platforms, facilities remote monitoring and management of patients undergoing MAT. In addition, the adoption of teleheath services has expanded access to MAT, allowing patients to consult with healthcare professionals virtually. This is particularly valuable for individuals in remote areas which boosts the medication-assisted treatment market. Furthermore, electronic health records systems streamline the management of patient information, ensuring that healthcare providers have comprehensive and up-to-date records. This promotes coordinated care, reduces administrative burdens, and enhances the overall quality of MAT programs.

Challenges

  • Regulatory Challenges across Regions- Regulatory framework and licensing requirements vary across regions, posing challenges to the expansion of medication-assisted treatment services. Integration and harmonization of the regulation process are necessary to overcome these obstacles.
  • Unequal distribution of healthcare resources, particularly in rural and low-income areas, restricts access to medication-assisted treatment.
  • The stigma linked with substance addiction and MAT is a significant hurdle to its adoption. Moreover, the lack of awareness among the general public regarding the implementation of MAT is also a hindrance.

Medication-assisted Treatment (MAT) Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

8.8%

Base Year Market Size (2025)

USD 11.2 billion

Forecast Year Market Size (2035)

USD 26.03 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Medication-assisted Treatment (MAT) Market Segmentation:

 Treatment Type Segment Analysis

The drug type segment in the medication-assisted treatment market is estimated to gain the largest revenue share of about 56% by 2035. The segment growth can be attributed to the factor that the pharma industry’s innovation in MAT, along with the growing awareness and acceptance of these treatments, further propels the drug-type segment expansion within the market. In addition, the market in the drug type segment is also influenced by the development of medication designed to assist individuals recovering from substance use disorder. According to recent data, substance use disorders cost employer-sponsored health insurance over USD 35 Billion in 2023.

End-User Segment Analysis

The hospital segment in the medication-assisted treatment market is estimated to gain the largest reevenue share of about 53% in the year 2035. The segment growth can be attributed to the factor that hospitals are integral in providing MAT due to their capacity for specialized care, medical expertise, and resources. In addition, hospitals often offer inpatient MAT programs, providing a controlled and supervised environment for individuals undergoing treatment. This approach allows for intensive medical monitoring and adjustment of medication dosages based on individual needs which stimulate the segment growth.

Our in-depth analysis of the global market includes the following segments:

          Treatment Type
  • Drug Type
  • Counseling & Therapies

          End-User
  • Hospital
  • Rehabilitation Clinic
  • Home Care Setting 
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Medication-assisted Treatment (MAT) Market - Regional Analysis

North American Market Insights

Medication-assisted Treatment market in the North America region is anticipated to hold the largest share of about 45% by the end of 2035. The regional growth is attributed to the factor that government, healthcare, organizations, and philanthropic entities in the region have allocated increased funding and resources to support MAT initiatives. This financial backing has enabled the expansion of treatment facilities, training programs, and public awareness campaigns. According to the National Institute on Drug Abuse, methadone treatment, including medication and integrated psychosocial & medical support services cost USD 6, 55, 20 per year in the US. In addition, the region has recognized the importance of MAT in treating opioid addiction and regulatory frameworks have been adapted to facilitate the integration of MAT into mainstream healthcare, ensuring better access to these treatments for individuals in need and stimulate the market in the region.

European Market Insights

The Europe medication-assisted treatment market is estimated to the second largest revenue share of about 30% by the end of 2035. The market’s expansion can be attributed to the multidisciplinary approach adopted by the European healthcare system to deal with substance disorders. MAT is integrated into this approach, combining medications with counseling and psychosocial support to address the complex nature of substance use disorders comprehensively. In addition, Community-based MAT programs have been established in various European regions. For example, a Harm reduction program encompasses interventions and policies that seek to mitigate the health, social, and economic harms of drug use to individuals, communities, and societies.  These initiatives focus on providing localized and accessible treatment options, emphasizing the importance of community involvement and support in the recovery process which further stimulate the medication-assisted treatment market in the region.

Medication-assisted Treatment (MAT) Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Medication-assisted Treatment (MAT) Market Players:

    • Indivior PLC
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Mallinckrodt Pharmaceuticals
    • Titan Pharmaceuticals, Inc.
    • Alkermes plc
    • Orexo AB
    • Mylan N.V.
    • Teva Pharmaceuticals Industries Ltd.
    • Lupin limited
    • Hikma Pharmaceuticals PLC
    • Novartis AG

Recent Developments

  • December 2023: Alkerems plc announced that it entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk , a leading global healthcare company. In terms of agreement, Alkermes will be entitled to one time cash payment of USD 92.5 Million for the facility and related assets, subject to customary adjustments in accordance with the agreement. In addition, Alkermes and Novo Nordisk also plan to enter into subcontracting arrangements to continue certain work currently performed at the facility for a period of time after closing the transaction, which may continue through the end of 2025.  
  • August 2023: Orexo AB announced that it continues to strengthen its patent portfolio and the new patent , No. US 11,737,980 provides protection for the OX640 product in the US until may 2041.  Moreover, Orexo’s proprietary drug delivery platform , amorphOX, is a powder made up of particles which are built using a unique combination of drug, carrier materials and optionally other ingredients.
  • Report ID: 5814
  • Published Date: Nov 28, 2025
  • Report Format: PDF, PPT
Festive Special Offer
$4550 $2450
  • Explore a preview of key market trends and insights
  • Review sample data tables and segment breakdowns
  • Experience the quality of our visual data representations
  • Evaluate our report structure and research methodology
  • Get a glimpse of competitive landscape analysis
  • Understand how regional forecasts are presented
  • Assess the depth of company profiling and benchmarking
  • Preview how actionable insights can support your strategy

Explore real data and analysis

Download Free Sample Report

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of medication-assisted treatment is estimated at USD 12.09 billion.

The global medication-assisted treatment market size crossed USD 11.2 billion in 2025 and is likely to register a CAGR of over 8.8%, exceeding USD 26.03 billion revenue by 2035.

By 2035, the North America region is projected to secure about 45% share in the medication-assisted Treatment Market, supported by intensified funding for MAT programs, expanded treatment capacity, and broader regulatory integration into mainstream healthcare owing to increased institutional backing.

Key players in the market include Indivior PLC, Mallinckrodt Pharmaceuticals, Titan Pharmaceuticals Inc., Alkermes plc, Orexo AB, Mylan N.V., Teva Pharmaceutical Industries Ltd., Lupin Limited, Hikma Pharmaceuticals PLC, Novartis AG.

Medication-assisted Treatment (MAT) Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Buy Now Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos